Phibro Animal Health Corporation (PAHC) gains on deep earnings
Phibro Animal Health Corporation (PAHC) gained after a strong earnings beat, but the bigger story is the depth behind it: profit growth outpaced revenue, Animal Health led segment momentum, and management raised fiscal 2026 and 2027 guidance above consensus, reinforcing the bullish setup.
Phibro Animal Health Corporation (PAHC) beat fiscal fourth-quarter expectations on both earnings and revenue, then raised its forward outlook with FY2027 adjusted EPS guidance above Wall Street estimates. The combination of a quarterly beat, stronger segment growth, and a higher earnings trajectory into 2027 drove the stock higher after hours and supports a constructive view for investors.
Phibro Animal Health Corporation (PAHC) Gains on Earnings Beat
Phibro Animal Health Corporation (PAHC) delivered a strong fiscal fourth-quarter result, with adjusted EPS of $0.85 versus the $0.72 estimate and revenue of $396.7M versus $382.51M consensus. Shares gained about 5% after hours, while the latest regular-session close stood at $36.09, up 0.45%.
Key Takeaways
PAHC posted adjusted EPS of $0.85 against a $0.72 estimate and revenue of $396.7M against $382.51M consensus.
Animal Health remained the strongest detailed segment in fiscal Q3, with sales up 13% to $291.2M.
Before the final quarter, fiscal 2026 sales guidance rose to $1.46B-$1.50B, while adjusted EBITDA guidance rose to $247M-$255M.
Fiscal 2027 adjusted EPS guidance of $3.41-$3.59 has a $3.50 midpoint, above the $3.07 Street consensus.
CEO Jack Bendheim highlighted portfolio diversity, Brazil's antimicrobial transition, and the new Verratain sustainability platform.
JPMorgan reiterated Overweight with a $58 price target and called the setup constructive for revenue and earnings growth into 2027.
The central PAHC earnings story is simple: the company beat on both major income statement lines, then paired the result with an above-consensus fiscal 2027 EPS outlook. That combination explains the sharp after-hours response better than the quarterly beat alone.
Financial Performance: PAHC Earnings Show Stronger Profit Growth
PAHC's latest quarter produced adjusted EPS of $0.85. The figure topped the $0.72 estimate and extended a record of quarterly EPS beats listed for August 2025, November 2025, February 2026, May 2026, and August 2026.
The recent earnings history also shows solid earnings power. Adjusted EPS reached $0.76 in May 2026, $0.87 in February, $0.73 in November, and $0.57 in August 2025. The latest $0.85 result therefore sits near the top of that five-quarter range, even though it trails the February reading of $0.87.
Revenue reached $396.7M, above the $382.51M estimate. The quarterly financial series records revenue of $0.40B for the June 2026 quarter, $0.38B for March, $0.37B for December, $0.36B for September, and $0.38B for June 2025. The latest top-line result therefore continues a pattern of quarterly revenue near or above $0.40B.
The detailed segment figures from fiscal Q3 show where that momentum came from. Animal Health generated $291.2M, up 13% year over year. Mineral Nutrition delivered $73.4M, up 10%, while Performance Products fell 17% to $18.9M.
Animal Health's growth had several layers. Legacy MFA sales rose 5%, new MFA sales contributed $95.9M, and nutritional specialties increased 8%. Vaccine sales rose 16%, driven by demand in Israel and higher autogenous vaccine sales. The annual segment history also lists vaccine revenue of $156.419M for the year ended June 30, 2026, up from $137.153M in the prior year.
Profit growth outpaced revenue growth in the detailed fiscal Q3 figures. Consolidated adjusted EBITDA rose 11% to $60M, adjusted net income increased 19%, and adjusted diluted EPS increased 19%. Animal Health adjusted EBITDA rose $8M, while Mineral Nutrition adjusted EBITDA was $5.1M and Performance Products adjusted EBITDA was $2.2M.
Several line items shaped that result. Higher gross profit supported earnings, but SG&A increased because of higher employee-related costs. Net interest expense rose $1.1M after an interest-rate swap expired. Foreign currency losses reached $1.9M, compared with foreign currency gains of $5.5M in the prior-year period.
The balance sheet also carries a clear operating signal. PAHC generated $66M of operating cash flow and invested $53M in capital expenditures during the 12 months ended March 31, 2026. Free cash flow was $13M, while inventory buildup ahead of tariffs and to meet customer demand reduced cash generation. Gross leverage was 3.1x and net leverage was 2.8x at quarter end.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Market Reaction and Analyst Response to PAHC Earnings
The immediate market response was positive. Reuters and Investing.com reported an after-hours gain of about 5% after the EPS and revenue beat. At the latest regular-session close, PAHC traded at $36.09, up 0.45%, with volume of 296,835 shares against an average of 265,487.
The stronger signal came from fiscal 2027 guidance. Management guided adjusted EPS to $3.41-$3.59, placing the midpoint at $3.50. Investing.com reported that the midpoint exceeded the $3.07 consensus estimate. That gap gives the market a forward earnings reason to revalue PAHC, rather than relying only on a one-quarter surprise.
JPMorgan reiterated an Overweight rating and kept its $58 price target. The bank described a “constructive setup for both revenue and earnings growth looking to 2027.” The target remains well above the latest regular-session price, which places the focus on whether PAHC can deliver the guided earnings path.
The broader analyst picture remains mixed. The current consensus data lists six Buy ratings, four Holds, and four Sells, producing an overall Buy consensus. TipRanks lists a Hold consensus, while prior price-target actions included Citi's reduction to $44 from $62 with a Neutral rating on May 14, 2026.
That split matters. PAHC has a fresh earnings beat and a bullish JPMorgan view, but the $44 Citi target and the Hold view on TipRanks show that regulatory and execution concerns have not disappeared. The stock's valuation story now depends more heavily on fiscal 2027 delivery.
Management Commentary: Brazil, Sustainability, and Financial Guidance
CEO Jack Bendheim framed PAHC as a diversified animal-health operator navigating different protein markets at once. His comments covered tight beef supply, early dairy stabilization, pressure on fats, positive poultry demand, and geopolitical volatility in the Middle East.
Our diversified portfolio and geographic reach allow us to navigate these different cycles effectively. - Jack Bendheim, CEO, Earnings Call
Brazil is the main regulatory issue in the PAHC narrative. Brazil removed growth-promotion and performance indications for certain antimicrobials, including virginiamycin and bacitracin, with a 180-day transition period. Virginiamycin sales in Brazil totaled $26M in fiscal 2025, and the product carries a margin above PAHC's company average.
This change has been in motion in Brazil for a long time. - Jack Bendheim, CEO, Earnings Call
Bendheim also pointed to Verratain, a sustainability platform launched through PAHC's partnership with VAXA. The company positions the product as a practical way for customers to address supply-chain emissions through feed systems. Management described the platform as being in the early stages of rollout.
CFO Glenn David supplied the financial framework. Before the final quarter, PAHC raised fiscal 2026 sales guidance to $1.46B-$1.50B from $1.45B-$1.50B. Adjusted EBITDA guidance moved to $247M-$255M from $245M-$255M, while adjusted net income guidance moved to $122M-$127M from $120M-$127M.
While this will be a headwind for fiscal year 2027, we are confident that growth in our business in other areas will more than offset this impact. - Glenn David, CFO, Earnings Call
The CFO's comment captures the investment case and the risk in one sentence. Brazil can pressure high-margin revenue, but Animal Health growth, vaccines, nutritional specialties, and new sustainability products provide the offset management expects.
Analyst Q&A Highlights from the PAHC Earnings Call
J.P. Morgan analyst Ekaterina Knyazkova pressed management on two specific points: the size of the Verratain opportunity and the product's position against Experior and Bovaer.
How are you thinking about the size of that opportunity, and how does the offering fit relative to some of the other products out there like Experior and Bovaer? - Ekaterina Knyazkova, J.P. Morgan, Earnings Call
Daniel Bendheim answered that the broader sustainability market tied to Fortune 500 Scope 3 pledges spans tens of billions to hundreds of billions of dollars, while stressing that Verratain's actual market depends on customer action. He defended the product's economics as a key differentiator.
What's special about Verratain is we believe it allows these companies to actually achieve what they set out to do and allows them to hit their pledges with a product that until now it was just not economically feasible for them to actually act on their pledges. - Daniel Bendheim, CEO Designate, Earnings Call
On competition, Bendheim argued that Experior and Bovaer address different emissions categories. He described one as focused on ammonia and the other on methane reduction, while positioning Verratain around carbon intensity and supply-chain emissions. The answer defended a multi-product market rather than treating the competing offerings as direct substitutes.
PAHC's latest earnings beat, $3.50 fiscal 2027 EPS midpoint, and JPMorgan's $58 target strengthen the case for a higher earnings trajectory. Brazil's $26M virginiamycin exposure and 2.8x net leverage remain important risks, but Animal Health growth and improving guidance give the bullish thesis measurable support.
+Why did Phibro Animal Health stock (PAHC) rise after earnings?
PAHC rose about 5% after hours because it beat fiscal fourth-quarter adjusted EPS and revenue estimates, reporting $0.85 per share versus $0.72 expected and $396.7 million in revenue versus $382.51 million expected. Investors also reacted positively to FY2027 adjusted EPS guidance of $3.41 to $3.59, which has a $3.50 midpoint above the $3.07 Street consensus.
+What were Phibro Animal Health's latest earnings and revenue results?
Phibro Animal Health reported adjusted EPS of $0.85 for the fiscal fourth quarter, topping the $0.72 estimate. Revenue came in at $396.7 million, above the $382.51 million consensus.
+What is PAHC's fiscal 2027 earnings guidance?
PAHC guided fiscal 2027 adjusted EPS to a range of $3.41 to $3.59, with a midpoint of $3.50. That midpoint is above the $3.07 consensus estimate, which signals stronger expected earnings growth than the market had priced in.
+Which business segments drove Phibro Animal Health's growth?
Animal Health was the strongest segment, with sales up 13% to $291.2 million in fiscal Q3. Mineral Nutrition also grew 10% to $73.4 million, while Performance Products declined 17% to $18.9 million.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on PAHC?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
